Dr. Robert M. Kottmann, M.D.
Pulmonology (Pulmonary Disease Physician)
University Of Rochester Medical Ctr, 601 Elmwood Avenue
Rochester, NY 14642
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 113
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NY license 230874 -
Critical Care Medicine (Internal Medicine) Physician
NY license 230874
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
- Highland Hospital Rochester, NY
Medical groups
- Pulmonary Disease Clinical Group (68 clinicians)
- Mary M PArkes Asthma and Pulmonary (36 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 113
- Services billed
- 347
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 99 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 40 | 35 |
| Test to measure expiratory airflow and volume | 40 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 39 | 22 |
| Test to examine how well the lungs exchange gases | 36 | 33 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 61 |
| Prednisone Other prescribers in Rochester, NY | 57 |
| Methylprednisolone Other prescribers in Rochester, NY | 31 |
| Pirfenidone | 30 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Rochester, NY | 25 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Rochester, NY | 21 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Rochester, NY | 20 |
| Mycophenolate Mofetil Other prescribers in Rochester, NY | 17 |
| Methotrexate (methotrexate sodium) Other prescribers in Rochester, NY | 17 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Rochester, NY | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $52,916 in research payments for these studies, mostly to the institutions running them.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.